Wednesday, October 23, 2019

DNA Testing Company Teams With Pharmaceutical Giant GlaxoSmithKline

-

When people mail their spit to 23andMe, they are likely thinking mainly about how their genetic material can be used to reveal their personal ancestral history. For years, though, the spit of consenting customers has also been used for scientific research ― profitable scientific research at times.

Now the pharmaceutical giant GlaxoSmithKline has made a $300 million, four-year commitment to support that effort and push it even further into the realm of drug development. The two companies will join forces to design and develop new, more targeted pharmaceuticals.

“Since the inception of 23andMe, our mission has been to help people access, understand and benefit from the human genome,” 23andMe founder Anne Wojcicki said Wednesday on her company’s blog.

The first project will delve into potential new Parkinson’s disease treatments.

“By working with GSK, we believe we will accelerate the development of breakthroughs,” Wojcicki said. 23andMe has linked up with other pharma companies, such as Pfizer, in the past for similar purposes.

GSK’s chief scientific officer, Hal Barron, said in a statement that he’s particularly excited about the partnership because “we know that drug targets with genetic validation have a significantly higher chance of ultimately demonstrating benefit for patients and becoming medicines.”

Customers are asked when they sign up with 23andMe whether they want to participate in research and can choose to opt out at any time. (Material that has already been sent in and included in a study cannot be withdrawn, however.) The company says most of its 5 million users opt in. On average, their material is used in more than 230 studies on subjects such as Parkinson’s disease or lupus, according to the company’s website.

The point of collaborating with pharmaceutical giants is to give researchers access to a database of genetic and personal information that’s much, much larger than what is typically available. Researchers can then try to identify new links between traits, diseases and genes ― and ideally, use that knowledge to inform therapies.

23andMe pitches customer participation in research as a chance to positively affect health care.

Some, however, see a lot to be concerned about.

Speaking with NBC News, Peter Pitts, president of the Center for Medicine in the Public Interest, suggested 23andMe customers be paid for opting in to the research.

“When two for-profit companies enter into an agreement where the jewel in the crown is your gene sequence and you are actually paying for the privilege of participating, I think that’s upside-down,” Pitts said.

He also questioned the steps 23andMe has taken to ensure customers’ privacy ― a risk the company also flags for customers. If its database were to be hacked, that information could be traced back to individual consumers and used against them.

Story by The Huffington Post.

Latest news

Millbourne Mayor Tom Kramer (D-Pa.) Goes Off On Local Papers For Using Town As ‘Political Pawn’ While Ignoring His Request to Print Letter of...

Democratic Mayor Tom Kramer of Millbourne, Pennsylvania has had it with his town being used as what...

Police locate DEAD BODY ditched on I-95 highway in Chester

Pennsylvania State Police swarmed the area just before the Commodore Barry Bridge Friday night for reports of...

Suspect sought after animals found burning alive in trashcan

Authorities are searching for clues after finding several opossums burning alive in Trainer, Pa., according to Justice...

Absconding Delaware County Sex Offender Caught

One of four sex offenders that absconded from a Delaware County ‘alcolholism treatment center’ was apprehended by authorities early Thursday morning, authorities tell yc.news.
- Advertisement -

Shaq partners with Miles College to launch HBCU initiative, and it’s an appetizing partnership to say the least

Each Historically Black College & University will soon have a Papa John's ... thanks to Shaquille O'Neal...

Missing Colwyn Boy, Tito Gleplay, 9, Found Safe

Police in Colwyn tell us that the missing 9-year-old boy has been found safe … Police say Tito Gleplay was located Wednesday and appears to be in good condition.

Must read

In 2015, District Attorney Kevin Steele claimed there was an ‘air-tight’ case against Bill Cosby, turns out there wasn’t

Montgomery County District Attorney Kevin Steele (D-Pa.) ran on a campaign promise to prosecute Bill Cosby in 2015, but he didn't have a case.
- Advertisement -

You might also likeRELATED
Recommended to you